ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD46 Antibody-drug Conjugate FOR46

Also written as “FOR46” and “FG-3246”.

Its studies are mostly in Prostatic Neoplasms · Multiple Myeloma, led by 2 companies.

Drug pageAnti-CD46 Antibody-drug Conjugate FOR46: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 20, 20183 company-led studies, 1 open or runningNext primary completion: Mar 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fortis Therapeuticsits history only20 open or runningphase 1since Jun 20, 2018Jun 20, 2018none ahead
Kyntra Bioits history only11 open or runningphase 2since Feb 19, 2025Feb 19, 2025Mar 31, 2028phase 2 · NCT06842498

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 20, 2018First study: phase 1 study in Prostate Cancer MetastaticNew to Fortis TherapeuticsFortis Therapeutics · NCT03575819 · 56 enrolled · United States
  2. Aug 21, 2018Phase 1 study in Multiple MyelomaFortis Therapeutics · NCT03650491 · 31 enrolled · United States
  3. Feb 19, 2025Kyntra Bio’s first study: phase 2 study in Prostatic NeoplasmsNew to Kyntra BioKyntra Bio · NCT06842498 · 75 planned · United States

Ahead

  1. Mar 31, 2028Primary completion: phase 2 study in Prostatic NeoplasmsKyntra Bio · NCT06842498

TargetBeta

CD46 →read by rule
“An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06842498Prostatic Neoplasms · United States2RecruitingKyntra BioMar 31, 202875
NCT03650491Multiple Myeloma · United States1CompletedFortis TherapeuticsJan 31, 202231
NCT03575819Prostate Cancer Metastatic · United States1CompletedFortis TherapeuticsNov 16, 202356

How it is read

Names in the registry

  • “FOR46”, 2 entries
  • “FG-3246”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.